Company Overview of Forward Pharma A/S
Forward Pharma A/S, a biopharmaceutical company, focuses on the provision of dimethyl fumarate (DMF) formulations for the treatment of various immune disorders. It develops FP187, a DMF formulation to treat relapsing remitting multiple sclerosis and psoriasis. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.
Ostergade 24A, 1
Founded in 2005
Key Executives for Forward Pharma A/S
Co-Founder and Chairman of the Board
Compensation as of Fiscal Year 2014.
Forward Pharma A/S Key Developments
Forward Pharma A/S Announces Appointment of Jan G. J. Van De Winkel to Board of Directors
Aug 12 14
Forward Pharma A/S announced that it has appointed Jan van de Winkel, Ph.D, President and Chief Executive Officer of Genmab, to its Board of Directors, effective immediately. Dr. van de Winkel is a co-founder of Genmab and currently serves as President and Chief Executive Officer. He has more than 20 years of experience in the therapeutic antibody field, is the author of over 300 scientific publications and has been responsible for more than 40 patents and pending patent applications. He is chairman of the board of directors of Regenesance and member of the board of directors of ISA Pharmaceuticals and Celdara Medical. Prior to Genmab, Dr. van de Winkel served as Vice President and Scientific Director of Medarex Europe.
Joel Sendek Joins Forward Pharma A/S as Chief Financial Officer
Aug 11 14
Forward Pharma A/S announced that Joel Sendek has been appointed Chief Financial Officer, effective August 5, 2014. Mr. Sendek will serve as a key member of the executive team providing strategic leadership for the company's financial functions and be responsible for the company's short and long-term financial objectives in support of the business strategy. Mr. Sendek joins the company from Stifel Financial Corp.
Forward Pharma A/S Auditor Raises 'Going Concern' Doubt
Aug 11 14
Forward Pharma A/S filed its Annual on Aug 11, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries